Leukemia, Lymphocytic, Chronic, B-Cell: all 1,648 studies
Page 12 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- Economic Analysis of Alliance A041202 CLL StudyActive, not recruitingNCT02414022
- Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic LeukemiaCompletedNCT02388048Phase 2
- Observational Study in CLL Patients Receiving BRCompletedNCT02381899
- Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell MalignancyCompletedNCT02381080Phase 1
- Heavy Light Chain in Chronic Lymphocytic LeukemiaStatus unknownNCT02377869
- Lenalidomide and Obinutuzumab for Previously Untreated CLLWithdrawnNCT02371590Phase 2
- Evaluation of the Immune Restoration Potential Of LenalidomideWithdrawnNCT02371577Phase 2
- A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and ComorbiditiesTerminatedNCT02336048Phase 1
- Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic LeukemiaCompletedNCT02316197Phase 1
- Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell MalignanciesStatus unknownNCT02315118Phase 1/2
- B-Cell Hematologic Malignancy Vaccination RegistryWithdrawnNCT02298816
- Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLCompletedNCT02296918Phase 1
- Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCTCompletedNCT02294552Phase 2
- Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)TerminatedNCT02292225Phase 1
- Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell MalignanciesCompletedNCT02290951Phase 1
- Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's TransformationWithdrawnNCT02285244Phase 2
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
- Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
- Tissue Collection for Biomarkers Determining Resistance to IbrutinibStatus unknownNCT02267590
- Study Evaluating Venetoclax in Subjects With Hematological MalignanciesCompletedNCT02265731Phase 1/2
- Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LymphomaTerminatedNCT02258555Phase 1
- Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic CancerCompletedNCT02240719Phase 1
- Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic LeukemiaCompletedNCT02232386Phase 2
- Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral InfectionsTerminatedNCT02231853Phase 1
- A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)Active, not recruitingNCT02229422Phase 1/2
- Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell TransplantationCompletedNCT02226861Phase 1
- Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)TerminatedNCT02200848Phase 1
- A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant PairsTerminatedNCT02200380Phase 2
- Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family MembersActive, not recruitingNCT02194387Not applicable
- Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT02194374Phase 1
- Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02160015Phase 1
- Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic LeukemiaActive, not recruitingNCT02157324Phase 1
- Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite ProjectStatus unknownNCT02156726
- Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaActive, not recruitingNCT02153580Phase 1
- Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic LeukemiaCompletedNCT02144623Early Phase 1
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL PatientsTerminatedNCT02137889Phase 1
- Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic LeukemiaApproved for marketingNCT02136511
- CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.CompletedNCT02132624Phase 1/2
- Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02131584Phase 2
- Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02129582Phase 1
- Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid MalignanciesCompletedNCT02128945Phase 1
- Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)SuspendedNCT02117336Phase 1
- Ribomustin in the First Line Therapy of Chronic Lymphocytic LeukemiaCompletedNCT02110394
- Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
- TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02100852Phase 1
- An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic LeukemiaCompletedNCT02080884
- Occupational Status and Hematological DiseaseCompletedNCT02057185
- Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT02046928Phase 2
- Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid LeukemiaTerminatedNCT02034227Phase 1/2
- Evaluation of Splenic Irradiation in Chronic Lymphatic LeukemiaWithdrawnNCT02020109
- Ruxolitinib in the Treatment of Chronic Lymphocytic LeukemiaCompletedNCT02015208Phase 1/2
- Ublituximab + Ibrutinib in Select B-cell MalignanciesCompletedNCT02013128Phase 1/2
- Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaActive, not recruitingNCT02007044Phase 2
- Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell MalignanciesCompletedNCT02006485Phase 1
- Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLLCompletedNCT02005289Phase 2
- A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.CompletedNCT01991184Phase 1
- Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic LeukemiaSuspendedNCT01982175Phase 2
- Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)Status unknownNCT01976520Phase 1
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
- Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantCompletedNCT01959477Early Phase 1
- AZD6738 First Time in Patient Multiple Ascending Dose StudyCompletedNCT01955668Phase 1
- Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT01944943Phase 2
- Pneumococcal Vaccine in Untreated CLL PatientsCompletedNCT01892618Phase 3
- Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01886859Phase 1
- Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic MalignanciesCompletedNCT01871675Phase 1
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19Status unknownNCT01864889Not applicable
- Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL PatientsStatus unknownNCT01862445
- Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic LeukemiaStatus unknownNCT01849939Phase 2
- A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 PharmacokineticsCompletedNCT01841489Phase 1
- BR in Patients With CLL With Comorbidities and/or Renal DysfunctionCompletedNCT01832922Phase 1
- Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative DisordersCompletedNCT01832597
- Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
- Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin LymphomaActive, not recruitingNCT01815749Phase 1
- Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic TransplantationCompletedNCT01809847Phase 2
- A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell MalignanciesCompletedNCT01805375Phase 1
- A Long-term Extension Study of PCI-32765 (Ibrutinib)Active, not recruitingNCT01804686Phase 3
- Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D InsufficiencyActive, not recruitingNCT01787409Not applicable
- Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
- Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01767766Phase 1
- Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.CompletedNCT01762202Phase 2
- Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable
- Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)WithdrawnNCT01754870Phase 2
- MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
- Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid MalignanciesTerminatedNCT01744912Phase 1
- Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT01744626Phase 1
- A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic LeukemiaWithdrawnNCT01739491
- Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to ChemotherapyStatus unknownNCT01735604Phase 1/2
- Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic LymphomaCompletedNCT01732861Phase 1
- Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLTerminatedNCT01728207Phase 1
- Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLLCompletedNCT01703364Phase 1/2
- Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaCompletedNCT01699152Phase 1
- A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic LeukemiaCompletedNCT01685892Phase 1
- A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaCompletedNCT01682616Phase 1
- Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic LeukemiaCompletedNCT01681563Phase 2
- A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive TreatmentStatus unknownNCT01678430Phase 3
- A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT01671904Phase 1
- Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic LeukemiaStatus unknownNCT01670812Phase 3
- Phase I Study of Milatuzumab for Graft Versus Host DiseaseTerminatedNCT01663766Phase 1